ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

Liu, Xudong; Zhao, Zihui; Dai, Wufei; Liao, Kuo; Sun, Qi; Chen, Dongjiang; Pan, Xingxin; Feng, Lishuang; Ding, Ying; Wei, Shiyou*上海交通大学; 四川大学; 中国科学院研究生院
Cancers2023-9DOI: 10.3390/cancers15174308
5阅读
引用收藏
分享

摘要

Simple Summary: Glioblastoma (GBM) is the deadliest primary central nervous system (CNS) cancer in adults despite aggressive treatment. Once progressed, the prognosis is very poor and the effective traditional medicine treatment options are limited, so the management of recurrent glioblastoma (rGBM) remains challenging. Immunotherapy has revolutionized the prospects for many cancer types, but the intrinsic complexity of treating intracerebral tumors and the highly immunosuppressive environment have hampered the development of effective immunotherapies. The current focus of research in rGBM is on combination therapy, identifying predictive markers, and establishing synergy between immunotherapy and standard treatment. In this review, we discuss the current state of immunotherapy for rGBM, its future directions, and the challenges associated with each strategy. @@@ Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neuro-oncology, and the survival status of patients after relapse usually means rapid deterioration, thus becoming the leading cause of death among patients. In recent years, immunotherapy has emerged as a promising strategy for the treatment of recurrent glioblastoma by stimulating the body's immune system to recognize and attack cancer cells, which could be used in combination with other treatments such as surgery, radiation, and chemotherapy to improve outcomes for patients with recurrent glioblastoma. This therapy combines several key methods such as the use of monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors, oncolytic viral therapy cancer vaccines, and combination strategies. In this review, we mainly document the latest immunotherapies for the treatment of glioblastoma and especially focus on rGBM.

学科与关键词

关键词
recurrent glioblastomaimmunotherapyCAR-T therapyimmune checkpoint inhibitorcancer vaccineoncolytic viral therapy
相关
加载中…
  • Current Immunotherapies for Glioblastoma Multiforme
    Huang, Boyuan; Li, Xuesong; Li, Yuntao; Zhang, Jin; Zong, Zhitao*; Zhang, Hongbo*Frontiers in Immunology, 2021, 11: 603911.被引 63
  • The immunosuppressive microenvironment and immunotherapy in human glioblastoma
    Zhang, Xuehua; Zhao, Leilei; Zhang, He; Zhang, Yurui; Ju, Huanyu; Wang, Xiaoyu; Ren, Huan*; Zhu, Xiao*; Dong, Yucui*Frontiers in Immunology, 2022, 13: 1003651.被引 6
  • Glucocorticoids and immune checkpoint inhibitors in glioblastoma.
    Kelly, William J; Gilbert, Mark R*Journal of Neuro-Oncology, 2021, 151(1): 13-20.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancers
发表日期
2023-09
卷期
第 15 卷, 第 17 期
页码
4308
DOI
10.3390/cancers15174308
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2022M720103]; Postdoctoral Program of Sichuan Province [TB2022018]; Fundamental Research Funds for the Central Universities [2023SCU12052]

作者

  • L

    Liu, Xudong (第一作者)

    univ chinese acad sci

  • Z

    Zhao, Zihui

    shanghai jiao tong univ

查看全部 10 位作者收起作者
  • D

    Dai, Wufei

    shanghai jiao tong univ

  • L

    Liao, Kuo

  • S

    Sun, Qi

    univ hong kong

  • C

    Chen, Dongjiang

  • P

    Pan, Xingxin

  • F

    Feng, Lishuang

    univ hong kong

  • D

    Ding, Ying

    univ chinese acad sci

  • W

    Wei, Shiyou (通讯)

    sichuan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417